Correlation between Long-Term Aspirin Use and F-Fluorodeoxyglucose Uptake in Colorectal Cancer Measured by PET/CT

Su, Binbin; Xu, Baixuan; Wan, Jun

doi:10.1371/journal.pone.0109459

Cited by 6 publications

(5 citation statements)

References 42 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It only suggested that the tumor N stage, TNM stage were independent prognostic factors. This result was consistent with the findings of SUV in colorectal cancer, and the reason for this result might be related to the small number of cases selected [30]. The 2-year disease-free survival rate of aspirin group was higher than that of the control group, suggesting that long-term oral aspirin can improve the disease-free survival of patients with nonsmall cell lung cancer.…”

Section: Discussionsupporting

confidence: 88%

Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis

et al. 2020

View full text Add to dashboard Cite

Background: 18 F-FDG is a glucose analogue whose metabolic index SUV can effectively reflect the metabolic level of tumor microenvironment. Aspirin can affect the uptake of 18F-FDG by cancer cells, reducing the SUVmax value of primary tumors, exerting antitumor effect. This study aimed to evaluate the prognostic value of long-term aspirin and the relationship between aspirin intake and PET parameters value of primary tumor in non-small cell lung cancer (NSCLC). Methods: Eighty-one NSCLC patients were recruited and divided into two groups: aspirin medication group and control group, who underwent surgery and had pathological diagnosis data between January 2012 and December 2016. Clinical characteristics were retrospective analyzed to evaluate the possibility of clinical prognosis, respectively. Kaplan-Meier curves and a Cox proportional hazard model were applied to evaluate the predictors of prognosis. Results: The PET/CT SUVmax of the primary tumor in the aspirin group was lower than that in the control group (P < 0.05). Compared with the control group, the SUVmax, SUVmean and TLG of the primary tumor in aspirin group were lower, but the MTV value had no significant difference. Cox regression analysis showed that N stage and TNM stage were predictors of the prognosis. There was a significant difference in the use of aspirin in NSCLC patients. Conclusion: Aspirin can reduce SUVmax, SUVmean and TLG in primary tumor and aspirin can improve the prognosis of patients with NSCLC.

show abstract

Section: Discussionsupporting

confidence: 88%

Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It has also been reported that 4 mM aspirin down-regulates GLUT1 expression and glucose consumption in hepatoma cells possibly through targeting NF-κB or NF-κB/HIF1α signaling [35], which coincides with our findings. A clinical report also showed that long-term use of aspirin inhibits F-18 fluorodeoxyglucose (FDG) uptake in colorectal cancer lesions [36]. Finally, we found a visible down-regulation of p-p65, indicating that 4 mM aspirin may inhibit activation of p65 subunit of NF-κB.…”

Section: Discussionsupporting

confidence: 66%

Aspirin, a potential GLUT1 inhibitor in a vascular endothelial cell line

Lou

Wang

et al. 2019

Open Medicine

View full text Add to dashboard Cite

AbstractRecent epidemiological and preclinical studies have revealed that aspirin possesses antitumor properties; one of the mechanisms results from inhibition of angiogenesis. However, the underlying mechanisms of such action remain to be elucidated, in particular, the effect of aspirin on glucose metabolism of vascular endothelial cells (ECs) has not yet been reported. Herein, we demonstrate that glucose transporter 1 (GLUT1), a main glucose transporter in ECs, can be down-regulated by aspirin. Exposure to 4-mM aspirin significantly decreased GLUT1 at the mRNA and protein level, resulting in impaired glucose uptake capacity in vascular ECs. In addition, we also showed that exposure to 4-mM aspirin led to an inhibition of intracellular ATP and lactate synthesis in vascular ECs, and a down-regulation of the phosphorylation level of NF-κB p65 was observed. Taken together, these findings indicate 4-mM aspirin inhibits glucose uptake and glucose metabolism of vascular ECs through down-regulating GLUT1 expression and suggest that GLUT1 has potential to be a target for aspirin in vascular ECs.

show abstract

“…According to the International Agency for Research on Cancer, 1.2 million novel cases of colorectal cancer were diagnosed worldwide in 2008, accounting for 8% of all cancer-related mortalities (2,3). The incidence of colorectal cancer is highest in developed countries and regions: Due to economic development and rapid urbanization in recent years in China, which has resulted in dietary and lifestyle changes within the population, the colorectal cancer morbidity and mortality rates in China are now higher than the average rates, worldwide (4,5).…”

Section: Introductionmentioning

confidence: 99%

“…Colorectal cancer operation is an important method for the treatment of colorectal cancer (5). The clinical manifestations of colorectal cancer may appear in the following ways: Altered defecation habits, stomach ache, abdominal masses, gastrointestinal hemorrhage, jaundice and a change in character of the stool.…”

Section: Introductionmentioning

confidence: 99%

Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway

Chen

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Colorectal cancer is the most common gastrointestinal cancer in the USA. Naphthazarin, one of the naturally available 1,4-naphthoquinone derivatives, is a natural bioactive molecule that exhibits an antitumor effect. To the best of our knowledge, this is the first study to investigate the anticancer effect of naphthazarin on cell proliferation and apoptosis in human SW480 colorectal cancer cells. In the present study, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and lactate dehydrogenase assays were performed to assess the effect of napthazarin on cell proliferation and cytotoxicity of SW430 cells, respectively. In addition, an Annexin V-fluorescein isothiocyanate/propidium iodide apoptosis assay and 4' ,6-diamidino-2-phenylindole staining were used to analyze cell and nuclei apoptosis of SW480 cells, respectively, following treatment with naphthazarin. Poly (ADP-ribose) polymerase (PARP), B-cell lymphoma 2 (Bcl-2) and B-cell associated X protein (Bax) protein expression was analyzed by western blot. Furthermore, caspase-3 activation was analyzed using a commercial kit. The results revealed that naphthazarin exhibited cell growth inhibition, an increase in cytotoxicity and apoptosis induction in SW480 cells, which was associated with activation of the Bax/Bcl-2 signaling pathway and cleaved caspase-3 activation. However, no significant differences in PARP expression were identified following treatment with naphthazarin in SW480 cells. Taken together, these results suggest that naphthazarin decreased cell viability and induced apoptosis of SW480 cells, indicating that naphthazarin may present a potential therapeutic agent for human colorectal cancer treatment.

show abstract

Correlation between Long-Term Aspirin Use and F-Fluorodeoxyglucose Uptake in Colorectal Cancer Measured by PET/CT

Cited by 6 publications

References 42 publications

Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis

Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis

Aspirin, a potential GLUT1 inhibitor in a vascular endothelial cell line

Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway

Contact Info

Product

Resources

About